Florey Institute’s in-house legal counsel recognised by Association of Corporate Counsel Australia
Posted: 5 November 2021 Florey Institute of Neuroscience and Mental Health’s in-house legal counsel, Ms Charlotte Weld-Blundell, is a finalist in the Association of Corporate Counsel Australia’s corporate lawyer awards. Charlotte was recognised in the ‘New to In-House’…
Have your say on Australia’s Biotechnology Future
Posted: 5 November 2021 You’re invited to have your say on the Biotechnology Blueprint, the Australian biotechnology industry’s decadal strategy. The Biotechnology Blueprint (the Blueprint) is a shared vision for the industry, by the industry. Led by AusBiotech, and…
ANDHealth CEO Appointed as a Member of the Council of the NHMRC
Posted: 27 October 2021 BioMelbourne Network Member ANDHealth has announced that CEO and Managing Director, Bronwyn Le Grice, has been appointed by the Hon Greg Hunt, the Australian Minister for Health and Aged Care, as a Member of…
Amplia appoints leading drug developer as Oncology Clinical Advisor
Posted: 27 October 2021 Amplia Therapeutics has today announced the appointment of internationally renowned drug developer, José Iglesias M.D, as its Oncology Clinical Advisor. Click here to read today’s ASX release Dr Iglesias has over 33 years’ experience in…
AdAlta presentations at AusBiotech invest and BIO-Europe
Posted: 25 October 2021 BioMelbourne Network member, AdAlta Limited, the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is pleased to announce that CEO and Managing Director, Dr Tim Oldham, will present at…
Joint Response to the HERC IP Framework Consultation
Posted: 20 October 2021 Research Australia, Medicines Australia, the Medical Technology Association of Australia (MTAA) and AusBiotech have responded to the HERC IP Framework Consultation paper. Together, they represent a significant proportion of the health R&D sector and…
WEHI and CSL to advance biologic therapies
Posted: 20 October 2021 Two of Melbourne’s most prominent medical research and drug development organisations, WEHI and CSL, have joined forces to create a Centre for Biologic Therapies. The new Centre combines WEHI’s expertise in immunology, cancer, inflammatory…
Brooker Consulting: Interim Executive Specialists
Posted 9 October 2021 Brooker Consulting have announced that Michelle Lyon has joined the team, specialising in interim executive appointments. Michelle has over 15 years’ experience in executive search, firstly partnering with FMCG and consumer-led businesses, then working…
360biolabs opens Brisbane-based specialty lab
Posted: 1 October 2021 Their Brisbane laboratory enables 360biolabs to further support clinical trials in the north-east region of Australia. As Australia’s leading and most comprehensive specialty laboratory, 360biolabs often receives requests to process samples for downstream enzymatic…
World’s first four dimensional post-COVID lung imagery
Posted 29 September 2021 The world’s first four-dimensional visual insight into the residual effects of COVID-19 or ‘long COVID’ providing an unprecedented ability for patients, clinicians and researchers to understand the ongoing impact of this disease has been…
Cancer Therapeutics Unveils New Identity
Posted 29 September 2021 BioMelbourne Network member Cancer Therapeutics (CTx CRC Ltd) has unveiled its new name and brand identity – Canthera Discovery. This transformation forms part of a wider organisational strategy to continue the incredible legacy of…
DMX-200 recommended for regulatory approval in COVID-19 study in India
Posted 27 September 2021 Highlights DCGI review complete and study formally recommended for regulatory approval Multiple clinical sites in India initiated Study protocol to recruit 600 participants with COVID-19 overall, with a safety analysis conducted after the first…
